阿托瓦斯塔丁对COVID-19结果的影响:对住院患者的倾向性得分匹配研究
Mohamad Amin Pourhoseingholi1, Omid Yazdani1, Mehdi Azizmohammad Looha2
1Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Current medicinal chemistry
|January 22, 2024
概括
在COVID-19患者中使用阿托尔瓦斯塔丁与减少住院死亡率有关,但没有影响重症监护室 (ICU) 的入院. 需要进一步的研究来证实这些关于COVID-19结果的发现.
科学领域:
- 心脏病学 心脏病学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 研究了阿托瓦斯塔丁对COVID-19患者结局的影响,包括生存,ICU入院和住院时间.
- 对2020年3月至2021年3月期间入院的COVID-19住院患者的回顾性分析.
研究的目的:
- 为了确定阿托瓦斯塔丁使用与COVID-19患者的预后之间的关联.
- 评估药物对死亡率,ICU入院和住院时间的影响.
主要方法:
- 回顾性队列研究涉及4322名COVID-19患者.
- 倾向性得分匹配 (PSM) 用于1:1患者对照平衡.
- 对阿托瓦斯塔丁对COVID-19预后的未调整和调整效应的分析.
主要成果:
- 阿托瓦斯塔丁的使用与COVID-19死亡率的降低有关 (HR:0.80;95%CI:0.68-0.95).
- 在阿托瓦斯塔丁和ICU入院之间没有发现显著的关联 (HR: 1.21; 95% CI: 0.99-1.47).
- 阿托瓦斯塔丁组的住院时间明显长 (p = 0.003);与埃诺沙巴林的联合治疗改善了存活率.
结论:
- 阿托瓦斯塔丁可以降低COVID-19患者的住院死亡率.
- 被认为是COVID-19的潜在有益的附加疗法.
- 推随机试验来验证这些观察结果.
更多相关视频
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
664
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
664
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
518
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
518
Time Course of Drug Effect
2.1K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
183
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
183
Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
166
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
166


